<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989429</url>
  </required_header>
  <id_info>
    <org_study_id>M518101-EU04</org_study_id>
    <secondary_id>2013‐001632‐21</secondary_id>
    <nct_id>NCT01989429</nct_id>
  </id_info>
  <brief_title>Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Group Phase III Multi-center Trial to Compare Twice Daily Topical Application of M518101, Daivonex® and Vehicle in Patients With Plaque Psoriasis III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Europe Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maruho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maruho Europe Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      M5181 - a novel vitamin D3 analogue - is currently under development for the treatment of
      plaque psoriasis and is being developed as a topical ointment formulation (M518101)

      Clinical and non-clinical studies indicate that M5181 is an effective treatment for plaque
      psoriasis.

      Based on the results of previous phase II trials the phase III trial has been designed to
      evaluate efficacy and safety of an 8-week treatment period with 50 μg/g M518101 in a larger
      population of patients with stable plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of psoriasis</measure>
    <time_frame>8 weeks</time_frame>
    <description>% reduction in mPASI(modified psoriasis area and severity index) will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response following 8 week treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>if mPASI is reduced by 50% or more at V7 , patients will be followed up for a further 8 weeks to evaluate time to relapse</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">788</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Daivonex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M518101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M518101</intervention_name>
    <description>8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse</description>
    <arm_group_label>Daivonex</arm_group_label>
    <arm_group_label>vehicle</arm_group_label>
    <arm_group_label>M518101</arm_group_label>
    <other_name>vitamin D3</other_name>
    <other_name>psoriasis treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged 18 years or older on the day of signing the informed
             consent form (ICF)

          -  Psoriasis patients with up to 20% affected body surface area ( BSA) (not including
             face or scalp)

          -  Investigator Global Assessment(IGA) of moderate to severe and who are suitable for
             topical therapy

        Exclusion Criteria:

          -  Pregnant or lactating females;

          -  Patients with known allergic reactions, irritations or sensitivity to vitamin D3
             derivatives drug hypersensitivity to other components of the investigational products;

          -  Patients who have been treated with topical steroids, topical immunosuppressive/
             immunomodulative drugs, topical vitamin D3 derivative, topical retinoids, anthralin,
             coal tar (except when used as shampoo) salicylic acid within 14 days of randomization

          -  Patients, who in the opinion of the investigator, have clinically relevant history or
             presence of any disease, any other skin disorder, any chronic medical condition which
             is not well controlled or surgical history which may interfere with the conduct of the
             trial

          -  Patients whose calcium test at screening exceed the upper limit of reference range
             (including serum calcium, albumin, phosphate, parathyroid hormone);

          -  Patients who have used any study drug (including experimental biologics) and/or
             participated in any clinical trial within the last 60 days before the day of
             randomization

          -  Patients who have been treated with any biologics for their psoriasis within 30 days
             or 5 half-lives (whichever is longer) of the biologic before the day of randomization
             the longest documented half-life of the biologic should be used to calculate the 5
             half-lives;

          -  Patients who have been treated with phototherapy (laser, oral steroids, oral retinoid,
             oral immunosuppressive/immunomodulative drugs, cytostatics, cyclosporine or
             methotrexate within 30 days of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D Thaci, Prof.Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Lubeck, Dermatology Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik für Dermatologie und Venerologie,</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC &quot;Chaika&quot; EOOD</name>
      <address>
        <city>Varna</city>
        <zip>9002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Hospital</name>
      <address>
        <city>Miskolc</city>
        <state>Csabai Kapu 9-11,</state>
        <zip>H-3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PI Hospital of Lithuanian University of Health Sciences</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSK MON Wojskowego Instytutu Medycznego</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <disposition_first_submitted>December 1, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 1, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 31, 2015</disposition_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>Vitamin D3</keyword>
  <keyword>topical</keyword>
  <keyword>ointments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

